<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>THERACYS- bacillus calmette-guerin substrain connaught live antigen injection, powder, lyophilized, for solution </strong><br>Sanofi Pasteur Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TheraCys safely and effectively. See full prescribing information for Theracys.<br><br> TheraCys<span class="Sup">®</span>, BCG Live (Intravesical)<br> Initial U.S. Approval: 1990</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING - RISK OF TRANSMISSION AND <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">TheraCys<span class="Sup">®</span>, BCG Live (Intravesical) contains live, attenuated mycobacteria. Because of the potential risk for transmission, prepare, handle, and dispose  of TheraCys as a biohazard material. (<a href="#S2">2</a>,<a href="#S5"> 5</a>)</span></li>
<li><span class="Bold">BCG is capable of dissemination when administered by the intravesical route. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, have been reported in patients receiving Intravesical BCG. (<a href="#S5">5</a>,<a href="#S6"> 6</a>)</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING - RISK OF TRANSMISSION AND <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">TheraCys<span class="Sup">®</span>, BCG Live (Intravesical) contains live, attenuated mycobacteria. Because of the potential risk for transmission, prepare, handle, and dispose  of TheraCys as a biohazard material. (<a href="#S2">2</a>,<a href="#S5"> 5</a>)</span></li>
<li><span class="Bold">BCG is capable of dissemination when administered by the intravesical route. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, have been reported in patients receiving Intravesical BCG. (<a href="#S5">5</a>,<a href="#S6"> 6</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">TheraCys is indicated for intravesical treatment and prophylaxis of urinary bladder carcinoma in situ (CIS) and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). (<a href="#S1">1</a>) </p>
<p class="Highlighta">Limitation of Use: TheraCys is not recommended for </p>
<ul>
<li>Stage Ta low-grade papillary tumors, unless they are judged to be at high risk of recurrence. (<a href="#S1">1</a>)</li>
<li>Immunization against <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. (<a href="#S1">1</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For intravesical instillation only.</span> </p>
<ul class="Square">
<li>Induction therapy: Administer one dose (81mg) TheraCys each week for 6 consecutive weeks. (<a href="#S2.1">2.1</a>)</li>
<li>Maintenance therapy: one dose given 3, 6, 12, 18 and 24 months following the initial dose. (<a href="#S2.1">2.1</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Square"><li>One dose of TheraCys consists of one 81mg vial of freeze-dried Bacillus Calmette and Guérin (BCG) reconstituted and diluted in 50 mL sterile, preservative-free saline. (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Square">
<li>Known systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to any component of TheraCys or after a previous administration of TheraCys. (<a href="#S4.1">4.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span> due to congenital or acquired immune deficiencies, concurrent disease, cancer therapy, or immunosuppressive therapy. (<a href="#S4.2">4.2</a>)</li>
<li>Symptoms or a previous history of systemic BCG reaction. (<a href="#S4.3">4.3</a>)</li>
<li>Concurrent febrile illness, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, or <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">macroscopic hematuria</span>. (<a href="#S4.4">4.4</a>)</li>
<li>Active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. (<a href="#S4.5">4.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Square">
<li>If TheraCys is administered within two weeks of either biopsy, TUR or traumatic bladder catheterization (associated with <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>), a systemic BCG reaction is much more likely to occur. (<a href="#S5.1">5.1</a>)</li>
<li>If a bacterial <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (UTI) occurs during the course of TheraCys treatment, withhold TheraCys instillation until complete resolution of the bacterial UTI. (<a href="#S5.3">5.3</a>)</li>
<li>If a patient develops persistent <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or experiences an acute febrile illness consistent with BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, permanently discontinue BCG instillations. Initiate treatment with 2 or more antimycobacterial agents promptly while conducting diagnostic evaluation, including cultures.  (<a href="#S5.2">5.2</a>)</li>
<li>Prepare and handle TheraCys using aseptic technique. Avoid needle stick injuries during the handling and mixing of TheraCys. (<a href="#S5.5">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions observed with TheraCys treatment at a rate &gt; 10% were transient <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span> and urgency, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, and mild <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. </p>
<p class="Highlighta">Symptoms of <span class="product-label-link" type="condition" conceptid="4227848" conceptname="Bladder irritability">bladder irritability</span> were reported in approximately 50% of patients receiving TheraCys, typically beginning 4-6 hours after instillation and lasting 24-72 hours. (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pharmacovigilance Department, Sanofi Pasteur Inc. at 1-800-822-2463 (1-800-VACCINE) or MEDWATCH at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Square">
<li>Immunosuppressants interfere with the development of the immune response to TheraCys and increase the risk of disseminated BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<a href="#S7.1">7.1</a>)</li>
<li>Antimicrobial therapy for other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may interfere with the effectiveness of TheraCys. (<a href="#S7.2">7.2</a>)</li>
<li>Intravesical treatment with TheraCys may induce a positive response to a tuberculin skin test. (<a href="#S7.3">7.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Bladder capacity: There is an increased risk of bladder <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contracture</span> when instilling TheraCys in patients with small bladder capacity. (<a href="#S8.6">8.6</a>) </p></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: RISK OF TRANSMISSION AND <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span></span></a></h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Dose and Schedule</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Preparation</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Administration</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Instructions for Disposal</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2	Immunosuppressed Persons</a></h2>
<h2><a href="#section-4.3" class="toc">4.3	Systemic BCG Reaction</a></h2>
<h2><a href="#section-4.4" class="toc">4.4	Patients with Increased Risk of BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></a></h2>
<h2><a href="#section-4.5" class="toc">4.5	Active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></a></h2>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Systemic BCG Reaction</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Bacterial <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> (UTI)</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Antimicrobial Therapy</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Handling Precautions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Latex</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Immunosuppressive Treatments</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Antimicrobial Therapy</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Clinical Test Interactions</a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	Small Bladder Capacity</a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h1><a href="#section-12" class="toc">14 	CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-13.1" class="toc">16.1	How Supplied</a></h2>
<h2><a href="#section-13.2" class="toc">16.2	Storage and Handling</a></h2>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: RISK OF TRANSMISSION AND <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span></span></h1>
<ul>
<li><span class="Bold">TheraCys®, BCG Live (Intravesical) contains live, attenuated mycobacteria. Because of the potential risk for transmission, prepare, handle, and dispose of TheraCys as a biohazard material. (<a href="#S2">2</a>,<a href="#S5"> 5</a>)</span></li>
<li><span class="Bold">BCG is capable of dissemination when administered by the intravesical route.  Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, have been reported in patients receiving Intravesical BCG. (<a href="#S5">5</a>,<a href="#S6"> 6</a>)</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First">TheraCys is indicated for intravesical use in the treatment and prophylaxis of carcinoma <span class="Italics">in situ</span> (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).</p>
<p>Limitation of Use: TheraCys is not recommended for</p>
<ul class="Disc">
<li>Stage Ta low-grade papillary tumors, unless they are judged to be at high risk of   recurrence.</li>
<li>Immunization against <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For intravesical instillation only. </span></p>
<p><span class="Bold">Do not inject intravenously, subcutaneously, intradermally or intramuscularly.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Dose and Schedule</h2>
<p class="First">Begin intravesical treatment of the urinary bladder a minimum of 14 days after biopsy or transurethral resection. Treatment consists of induction and maintenance therapy. For the induction therapy, administer one dose (81mg) of TheraCys each week for 6 consecutive weeks. For the maintenance therapy, administer one dose at 3, 6, 12, 18, and 24 months following the initial dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Preparation</h2>
<p class="First">To avoid cross-contamination, do not prepare parenteral drugs in areas where TheraCys has been prepared. Handle and dispose of all equipment, supplies and receptacles in contact with TheraCys as biohazardous waste (or material). Wear gloves and eye protection and take precautions to avoid contact of BCG with broken skin. In addition, if the preparation cannot be performed in a biocontainment hood, wear a mask and gown.</p>
<p>Use aseptic techniques.</p>
<ul>
<li>Clean surface of the rubber stopper of the vial of TheraCys with a suitable antiseptic. Do <span class="Underline">not</span> remove the rubber stopper from the vial.</li>
<li>Using a syringe, draw up 3 mL of sterile preservative-free saline solution.</li>
<li>Pierce the rubber stopper in the vial of freeze-dried material.</li>
<li>Hold the vial of freeze-dried material upright and pull the plunger of the syringe back to create a mild vacuum in the vial.</li>
<li>Release the plunger and allow the vacuum to pull the saline from the syringe into the vial of freeze-dried material. After all the saline has passed into the freeze-dried material, remove the syringe.</li>
<li>Shake the vial gently until a fine, even suspension results. Avoid foaming since this will prevent withdrawal of the proper dose.</li>
<li>Withdraw the entire contents (approximately 3 mL) of the reconstituted material into the syringe. Return the vial to an upright position before removing the syringe from the vial.</li>
<li>Further dilute the reconstituted material from the vial (1 dose) in sterile<span class="Bold">, </span>preservative-free saline to a final volume of 50 mL for intravesical instillation.</li>
<li>Use TheraCys immediately after reconstitution. Any delay between reconstitution and administration must not exceed 2 hours at a temperature between 2° and 25°C (35° and 77°F).</li>
</ul>
<p>Do not use any reconstituted product that exhibits flocculation or clumping that cannot be dispersed with gentle <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>.</p>
<p>Do not expose reconstituted product to sunlight, direct or indirect.</p>
<p>Keep exposure to artificial light to a minimum.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Administration</h2>
<p class="First">Insert a urethral catheter into the bladder under aseptic conditions, drain the bladder, instill 50 mL suspension of TheraCys slowly by gravity, and then withdraw the catheter.</p>
<p>Have the patient retain the suspension for as long as possible for up to two hours. During the first 15 minutes following instillation, the patient should lie prone. Thereafter, allow the patient to be in an upright position.</p>
<p>At the end of 2 hours, have the patient void in a seated position for safety reasons.</p>
<p>Instruct the patient to increase fluid intake in order to flush the bladder in the hours following BCG treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Instructions for Disposal</h2>
<p class="First">Immediately place unused product, packaging, and all equipment and materials used for instillation of the product (e.g., syringes, catheters) in a container for biohazardous materials, and dispose of them according to local requirements applicable to biohazardous materials.</p>
<p>Properly dispose of voided urine during the 6 hr period following TheraCys instillation with an equal volume of 5% hypochlorite solution. [<span class="Italics">See<a href="#S17"> Patient Counseling Information (17)</a>]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">One dose of TheraCys consists of one 81 mg vial of freeze-dried BCG reconstituted and diluted in 50 mL sterile, preservative-free saline.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Known systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to any component [See <span class="Italics"><a href="#S5.6">Latex (5.6)</a></span>and <span class="Italics"><a href="#S11">Description (11)</a></span>] of TheraCys or after a previous administration of TheraCys or after a previous administration of TheraCys or a medicinal product containing the same substances is a contraindication to the administration of TheraCys.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2	Immunosuppressed Persons</h2>
<p class="First">Because of the risk of disseminated BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, immunosuppressed persons with congenital or acquired immune deficiencies, whether due to concurrent disease (e.g., AIDS, <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>), cancer therapy (e.g., cytotoxic drugs, radiation), or immunosuppressive therapy (e.g., corticosteroids) should not receive TheraCys. [See <span class="Italics"><a href="#S7.1">Drug Interactions (7.1)</a></span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.3"></a><a name="section-4.3"></a><p></p>
<h2>4.3	Systemic BCG Reaction</h2>
<p class="First">Do not use TheraCys  in patients with current symptoms or a previous history of systemic BCG reaction. [See <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>]</p>
<p>A minimum of 14 days must elapse before TheraCys is administered following biopsy, TUR, or traumatic catheterization.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.4"></a><a name="section-4.4"></a><p></p>
<h2>4.4	Patients with Increased Risk of BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></h2>
<p class="First">Postpone TheraCys treatment until resolution of a concurrent febrile illness, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, or <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">macroscopic hematuria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.5"></a><a name="section-4.5"></a><p></p>
<h2>4.5	Active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></h2>
<p class="First">Do not administer TheraCys to persons with active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. Rule out active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> before starting treatment with TheraCys.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Systemic BCG Reaction</h2>
<p class="First">A systemic BCG reaction is a systemic granulomatous illness, which may occur subsequent to exposure to TheraCys. Because it is usually difficult to isolate BCG organisms from affected organs, the extent such a reaction is caused by an infectious process versus an inflammatory <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> often is unclear. "Systemic BCG reaction" may be defined as the presence of any of the following signs, if no other etiologies for such signs are detectable: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> ≥39.5°C (≥103.1°F) for ≥12 hours; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> ≥38.5°C (≥101.3°F) for ≥48 hours; <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>; <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>; other organ dysfunction outside of the genitourinary tract with granulomatous <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> on biopsy; or the classical signs of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, acute <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, and <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>. If TheraCys is administered within two weeks of either biopsy, TUR or traumatic bladder catheterization (associated with <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>), a systemic BCG reaction is much more likely to occur. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> has been reported with the use of TheraCys in association with systemic BCG reaction in post-marketing experience.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></h2>
<p class="First">To help prevent serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, avoid <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> and/or introduction of contaminants to the urinary tract. Wait a minimum of 14 days after traumatic catheterization before administering TheraCys. Resume TheraCys treatment according to the original schedule.</p>
<p>BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of <span class="product-label-link" type="condition" conceptid="4311963" conceptname="Aneurysm">aneurysms</span> and prosthetic devices (including arterial grafts, cardiac devices, and artificial joints) have been reported following intravesical administration of BCG. The risk of these ectopic BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> has not been determined. The benefits of TheraCys therapy must be carefully weighed against the possibility of an ectopic BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in patients with pre-existing <span class="product-label-link" type="condition" conceptid="312336" conceptname="Arterial aneurysm">arterial aneurysms</span> or prosthetic devices of any kind.</p>
<p>Some male genitourinary tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span>/<span class="product-label-link" type="condition" conceptid="4150043" conceptname="Epididymitis">epididymitis</span>) have been refractory to multiple drug antituberculous therapy and required orchiectomy.</p>
<p>Monitor patients for the presence of symptoms and signs of toxicity after each intravesical treatment. If a patient develops persistent <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or experiences an acute febrile illness consistent with BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, permanently discontinue BCG instillations, evaluate and treat the patient immediately for BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and seek an infectious diseases consultation. As standard therapy for BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, promptly initiate treatment with 2 or more antimycobacterial agents while conducting diagnostic evaluation, including cultures. Do not use single antibiotic therapy. Negative cultures do not rule out <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>TheraCys is not sensitive to pyrazinamide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Bacterial <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> (UTI)</h2>
<p class="First">If a bacterial <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (UTI) occurs during the course of TheraCys treatment, withhold TheraCys instillation until complete resolution of the bacterial UTI.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Antimicrobial Therapy</h2>
<p class="First">Do not use antimycobacterial drugs (e.g., isoniazid) prophylactically to prevent the local, irritative side effects of TheraCys. They may affect the effectiveness of TheraCys and there are no data to suggest that the acute, local urinary tract symptoms common with intravesical BCG are due to <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Handling Precautions</h2>
<p class="First">Because TheraCys contains live mycobacteria, prepare, handle and dispose of TheraCys, and all equipment, supplies and receptacles in contact with TheraCys, as biohazardous waste (or material). Use aseptic techniques, wear gloves and eye protection, and take precautions to avoid contact of TheraCys with broken skin. Avoid needle stick injuries during the handling and mixing of TheraCys.</p>
<p>BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> have been reported in health care workers preparing BCG for administration. Nosocomial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> have been reported in immunosuppressed patients receiving parenteral drugs that were prepared in areas in which BCG was prepared.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Latex</h2>
<p class="First">The stopper of the vial for this product contains natural rubber latex, which may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<p class="First">The most common adverse reactions observed with TheraCys treatment at a rate &gt; 10% were transient <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span> and urgency, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, and mild <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a medicinal product cannot be directly compared to rates in the clinical trials of another medicinal product and may not reflect the rates observed in practice.</p>
<p>Administration of TheraCys causes an inflammatory response in the bladder, thus requiring careful patient monitoring. Symptoms of <span class="product-label-link" type="condition" conceptid="4227848" conceptname="Bladder irritability">bladder irritability</span> are reported in approximately 50% of patients receiving TheraCys and typically begin 4-6 hours after instillation and last 24-72 hours. The irritative reactions usually are seen following the third instillation and tend to increase in severity after each administration. There is no evidence that dose reduction or antituberculous drug therapy can prevent or lessen the irritative symptoms of TheraCys.</p>
<p>In a clinical trial conducted in the United States, patients with stage Ta or T1 papillary tumor with 2 or more recurrences within the last 12 months, with carcinoma <span class="Italics">in situ</span> (CIS), or with both of these conditions, were randomized to receive treatment with intravesical TheraCys or doxorubicin. Prior therapy with either BCG or doxorubicin was not allowed. Patients with muscle-invasive cancers or incomplete resection of papillary tumors were not eligible. One-hundred and twelve patients received TheraCys in 6 weekly instillations, followed by single instillations at 3, 6, 12, 18, and 24 months after enrollment, and were included in safety analyses. In the control group, 119 patients received doxorubicin in 5 weekly treatments, followed by 11 monthly treatments. Safety information was collected prior to each treatment dose.</p>
<p>Table 1 shows the frequency of adverse reactions observed in this trial. Local irritative symptoms were more common with TheraCys than with doxorubicin; however, grade ≥ 3 irritative toxicity was similar, occurring in approximately 2-7% of patients. Systemic symptoms (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>) were also more common with TheraCys. Overall, grade ≥ 3 toxicities were seen in 26 patients (23%) treated with TheraCys and 25 patients (21%) treated with doxorubicin. TheraCys treatment was discontinued in twelve patients due to toxicity.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Adverse Reactions Reported in Patients Treated with TheraCys in a Trial Conducted in the United States</span></caption>
<col align="center" valign="top" width="28%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<thead>
<tr class="First">
<th class="Lrule" align="center"></th>
<th class="Botrule Lrule Rrule" align="center" colspan="4">Study  Arm</th>
</tr>
<tr>
<th class="Lrule" align="center">System/Organ Class</th>
<th class="Botrule Lrule" align="center" colspan="2">TheraCys  (N=112)</th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">Doxorubicin  (N=119)</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule" align="center">Adverse reaction</th>
<th class="Lrule" align="center">All Grades<br>%</th>
<th class="Lrule" align="center">Grade ≥3<br>%</th>
<th class="Lrule" align="center">All Grades<br>%</th>
<th class="Lrule Rrule" align="center">Grade ≥3<br>%</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span></td>
<td class="Rrule" align="center">29.5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">19.3</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">17.9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">17.6</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">4.2</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">Blood and Lymphatic System Disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">20.5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">24.4</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Rrule" align="center">5.4</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5.9</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span>/ <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">Metabolism and Nutrition Disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center">10.7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5.0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3.4</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Cardiac (unclassified)</td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3.4</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">16.1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">8.4</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">6.3</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1.7</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2.5</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">Hepatobiliary Disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Liver involvement</td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span></td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2.5</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">Musculoskeletal, Connective Tissue, and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">Bone Disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>/<span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>/ <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span></td>
<td class="Rrule" align="center">7.1</td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">4.2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">Flank pain</span></td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">Renal and Urinary Disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></td>
<td class="Rrule" align="center">51.8</td>
<td class="Rrule" align="center">3.6</td>
<td class="Rrule" align="center">40.3</td>
<td class="Rrule" align="center">5.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span></td>
<td class="Rrule" align="center">40.2</td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">28.6</td>
<td class="Rrule" align="center">4.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td class="Rrule" align="center">39.3</td>
<td class="Rrule" align="center">7.1</td>
<td class="Rrule" align="center">27.7</td>
<td class="Rrule" align="center">6.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">Urinary urgency</span></td>
<td class="Rrule" align="center">17.9</td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">11.8</td>
<td class="Rrule" align="center">2.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Renal toxicity (NOS)</td>
<td class="Rrule" align="center">9.8</td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">9.2</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span></td>
<td class="Rrule" align="center">6.3</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4048710" conceptname="Bladder pain">Bladder cramps</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="center">6.3</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5.0</td>
<td class="Rrule" align="center">1.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4232015" conceptname="Contracted bladder">Contracted bladder</span></td>
<td class="Rrule" align="center">5.4</td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">5.0</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Tissue in urine</td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1.7</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Ureteral obstruction</td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4012198" conceptname="Pain in female genitalia">Genital pain</span></td>
<td class="Rrule" align="center">9.8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">13.4</td>
<td class="Rrule" align="center">1.7</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">General Disorders and Administration Site Conditions</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td class="Rrule" align="center">40.2</td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">14.3</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> (&gt;38°C)</td>
<td class="Rrule" align="center">38.4</td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">9.2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Rrule" align="center">33.9</td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">5.9</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following additional adverse reactions have been identified during post-approval use of TheraCys. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></p>
<p>BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:  BCG is capable of dissemination when administered by the intravesical route. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> with associated mortality, have been reported. BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> have also been reported in eye, lung, liver, bone, bone marrow, kidney, regional lymph nodes, peritoneum, genitourinary tract (<span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span>/<span class="product-label-link" type="condition" conceptid="4150043" conceptname="Epididymitis">epididymitis</span>), and prostate (e.g., Granulomatous <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span>). BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of <span class="product-label-link" type="condition" conceptid="4311963" conceptname="Aneurysm">aneurysms</span> and prosthetic devices (including arterial grafts, cardiac devices and artificial joints) has also been reported.</p>
<p>Joint symptoms (<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>), ocular symptoms (including <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, granulomatous choreoretinitis), urinary symptoms (including <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span>), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, alone or in combination (Reiter's syndrome), have been reported following administration of TheraCys. For the reports of Reiter's syndrome, the risk seems to be more elevated among patients who are positive for HLA-B27.</p>
<p><span class="product-label-link" type="condition" conceptid="4142194" conceptname="Renal abscess">Renal abscess</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.3"></a><p></p>
<p class="First">Skin and Subcutaneous Tissue Disorders</p>
<p><span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">Erythema nodosum</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.4"></a><p></p>
<p class="First"><span class="Bold">Renal and Urinary Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> (including <span class="product-label-link" type="condition" conceptid="4177206" conceptname="Tubulointerstitial nephritis">tubulointerstitial nephritis</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> and <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>)</p>
<p><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span> (including bladder tamponade and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">feeling of residual urine</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.5"></a><p></p>
<p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p>
<p>Flu-like symptoms</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.6"></a><p></p>
<p class="First"><span class="Bold">Investigations (Laboratory Tests)</span></p>
<p>Abnormal/increased blood creatinine or blood urea nitrogen (BUN)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Immunosuppressive Treatments</h2>
<p class="First">Treatments using immunosuppressants, myelosuppressants, or radiation interfere with the development of the immune response to TheraCys and increase the risk of disseminated BCG <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Carefully consider TheraCys treatment decisions in patients with a condition that may require future mandatory <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> (e.g., awaiting an organ transplant, <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Antimicrobial Therapy</h2>
<p class="First">Antimicrobial therapy for other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may interfere with the effectiveness of TheraCys.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Clinical Test Interactions</h2>
<p class="First">Intravesical treatment with TheraCys may induce a positive response to a tuberculin skin test [tuberculin purified protein derivative (PPD)], which may complicate future interpretations of skin test reactions to PPD when used to diagnose suspected <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infections</span>. If a patient's reactivity to PPD needs to be determined, the Tuberculin Skin Test should be conducted before administration of TheraCys.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category C </span></p>
<p>Animal reproduction studies have not been conducted with TheraCys. It is also not known whether TheraCys can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. TheraCys should not be given to a pregnant woman unless clearly needed. Women should be advised not to become pregnant while on therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether TheraCys can be excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from TheraCys in nursing infants, it is advisable to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">Safety and effectiveness of TheraCys for the treatment of superficial <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">In clinical studies with TheraCys, analyses evaluating the differences in safety and efficacy between study subjects 65 years of age and older versus younger subjects were not performed. No other data are available about the potential impact of age on the safety and efficacy of TheraCys.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	Small Bladder Capacity</h2>
<p class="First">In patients with small bladder capacity, consider increased risk of bladder <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contracture</span> when making the decision to treat with TheraCys.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">Overdosage occurs if more than one vial of TheraCys is administered per instillation. If overdosage occurs, closely monitor the patient for signs of active local or systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> [See <span class="Italics"><a href="#S5">Warnings and Precautions (5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">TheraCys, BCG Live (Intravesical) is a freeze-dried preparation made from the Connaught <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Bacillus Calmette and Guérin</span>, which is an attenuated <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Mycobacterium bovis.</span></p>
<p>The BCG organisms in the product are grown on media containing potatoes, glycerine, asparagine, citric acid, potassium phosphate, magnesium sulfate, ferric ammonium citrate, calcium chloride, copper sulfate, and zinc sulfate. Monosodium glutamate is added to the BCG organisms prior to freeze-drying.</p>
<p>Each vial of TheraCys contains 81 mg of freeze-dried BCG. The freeze-dried BCG does not contain any preservative.</p>
<p>One dose of TheraCys consists of one 81mg vial of freeze-dried BCG reconstituted and diluted in 50 mL sterile, preservative-free saline.</p>
<p>The BCG organisms from the vial are viable. <span class="Italics">In vitro</span> potency is determined by an assay of live BCG organisms based on the number of colonies observed when grown on solid medium. The reconstituted product contains 10.5 ± 8.7 × 10<span class="Sup">8</span> colony-forming units (CFU) per vial.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">When administered intravesically as a cancer therapy, BCG promotes a local acute inflammatory and sub-acute granulomatous reaction with macrophage and lymphocyte infiltration in the urothelium and lamina propria of the urinary bladder. The exact mechanism of action is unknown, but the anti-tumor effect appears to be T-lymphocyte-dependent.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-12"></a><p></p>
<h1>14 	CLINICAL STUDIES</h1>
<p class="First">The efficacy and safety of TheraCys were compared to doxorubicin hydrochloride in a multicenter, open-label, randomized clinical trial, in patients with carcinoma <span class="Italics">in situ</span> (CIS) of the urinary bladder, recurrent Ta/T1 papillary tumors of any grade of the urinary bladder, or both. A total of 285 patients were randomized: 142 to treatment with doxorubicin (69 CIS and 73 non-CIS) and 143 to treatment with TheraCys (70 CIS and 73 non-CIS). All papillary tumors were completely resected prior to trial entry. TheraCys was administered intravesically weekly for 6 weeks, with additional single instillations at 3, 6, 12, 18, and 24 months following the initiation of treatment (total of 11 instillations over 2 years). The initial treatment with doxorubicin was given within 3 days of TUR, followed by 4 weekly treatments and then by 11 monthly treatments (total of 16 instillations over 1 year). <span class="product-label-link" type="condition" conceptid="45771295" conceptname="Cytology">Cytology</span> and cystoscopy were obtained every 3 months for 2 years. Disease-free survival and 2-year disease-free survival were evaluated and an intent-to-treat analysis was performed.</p>
<p>The median age of patients treated with doxorubicin was 70 years (CIS; range 31-88 years) and 65 years (non-CIS; range 38-95 years), while the median age was 66 years (CIS; range 33-83 years) and 67 years (non-CIS; 24-95 years) in patients treated with Theracys. The racial distribution was 89% White, 5% Black and 6% Other in the doxorubicin treatment arm and 95% White, 3% Black and 2% Other in the Theracys treatment arm.</p>
<p>For patients with CIS, the complete response rate (i.e., negative biopsies and urine <span class="product-label-link" type="condition" conceptid="45771295" conceptname="Cytology">cytology</span>) within 6 months of the initiation of treatment was 33% with doxorubicin and 71% with TheraCys (p &lt; 0.001, Fisher's Exact Test). The probability of being disease-free at 2 years was 23% with doxorubicin and 51% with TheraCys (p &lt; 0.001, Z Test). The median disease-free survival was 4.9 months for doxorubicin and 30 months for TheraCys (p &lt; 0.001, Log Rank Test).</p>
<p>For patients with Ta/T1 papillary tumors only, the 2-year disease-free survival was 29% with doxorubicin and 50% with TheraCys (p = 0.008, Z Test). The median disease-free survival was 10.5 months with doxorubicin and 22.5 months with TheraCys (p = 0.001, Log Rank Test).</p>
<p>The results are summarized in Table 2.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2: TheraCys Efficacy in a Clinical Trial Conducted in the United States</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<thead>
<tr class="Botrule First">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center" colspan="2">Carcinoma<span class="Italics"> in situ</span>
</th>
<th class="Lrule Rrule" align="center" colspan="2">Ta/T1 Papillary Tumors</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">Doxorubicin<br>N = 69</th>
<th class="Lrule" align="center">TheraCys<br>N = 70</th>
<th class="Lrule" align="center">Doxorubicin<br>N = 73</th>
<th class="Lrule Rrule" align="center">TheraCys<br>N = 73</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Based on Kaplan-Meier estimates.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Complete Response</span></td>
<td class="Rrule" align="center">23 (33%)</td>
<td class="Rrule" align="center">50 (71%)</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Median Disease-free Survival<a href="#footnote-1" class="Sup">*</a></span></td>
<td class="Rrule" align="center">4.9 Months</td>
<td class="Rrule" align="center">30 Months</td>
<td class="Rrule" align="center">10.5 Months</td>
<td class="Rrule" align="center">22.5 Months</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">2-Year Disease-free Survival<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></td>
<td class="Rrule" align="center">23%</td>
<td class="Rrule" align="center">51%</td>
<td class="Rrule" align="center">29%</td>
<td class="Rrule" align="center">50%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">95% Confidence Interval</span></td>
<td class="Rrule" align="center">(15%, 35%)</td>
<td class="Rrule" align="center">(41%, 65%)</td>
<td class="Rrule" align="center">(20%, 41%)</td>
<td class="Rrule" align="center">(39%, 63%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.1"></a><a name="section-13.1"></a><p></p>
<h2>16.1	How Supplied</h2>
<p class="First">Vial, 1 dose of the freeze dried product. NDC No. 49281-880-58; in package of 1 vial, NDC No. 49281-880-03</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="S16.2"></a><a name="section-13.2"></a><p></p>
<h2>16.2	Storage and Handling</h2>
<ul class="Disc">
<li>Store at 2 to 8 °C (35 to 46 °F).</li>
<li>Do not expose to sunlight, direct or indirect.</li>
<li>Keep exposure to artificial light to a minimum.</li>
<li>Do not use beyond the expiration date.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<ul class="Disc">
<li>Inform patients to notify their   physicians if they have any of the following symptoms that  last more than   48 hours or increase in severity: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, flu-like   symptoms, increased <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or an increase burning or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on urination.</li>
<li>Inform patients to notify their   physicians right away if they experience any of the following: increased urinary   urgency or frequency of urination, <span class="product-label-link" type="condition" conceptid="437038" conceptname="Blood in urine">blood in urine</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>,   irritation, or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</li>
<li>Inform patients that TheraCys   contains live mycobacteria that can be present in voided urine. Advise   patients on proper procedures to minimize environmental contamination of   voided urine.<ul class="Circle">
<li>For 6 hours after treatment, void while seated to minimize splashing of urine.</li>
<li>For 6 hours after treatment, disinfect voided urine by adding an approximately equal volume of household bleach   (5% hypochlorite solution) into the toilet bowl and allowing the bleach and urine to stand for 15 minutes prior to <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>.</li>
<li>Family and close contacts should avoid contact with voided urine.</li>
</ul>
</li>
<li>Increase fluid intake to flush   the bladder for several hours after treatment with TheraCys, unless   medically contraindicated.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">Printed in Canada</p>
<p>Manufactured by:<br><span class="Bold">Sanofi Pasteur Limited</span><br>Toronto Ontario Canada</p>
<p>Distributed by:<br><span class="Bold">Sanofi Pasteur Inc.</span><br>Swiftwater PA 18370 USA</p>
<p>R8-0913 USA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 81 mg Vial Label</span></p>
<p>NDC <span class="Bold">49281-880-58</span></p>
<p><span class="Bold">BCG Live (Intravesical)</span></p>
<p><span class="Bold Italics">THERACYS</span><span class="Sup">®</span></p>
<p>81 mg. Contains live bacteria.</p>
<p>Store at 2° to 8°C (35° to 46°F). </p>
<p>Protect from light. Reconstitute for use.</p>
<p><span class="Bold">Sanofi Pasteur Limited</span></p>
<p><span class="Bold">BCG</span></p>
<p>1 Dose</p>
<p><span class="Italics">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1 Dose Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e456333-5a25-4484-84bf-53ece67c000a&amp;name=theracys-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 81 mg Vial Carton (No Diluent)</span></p>
<p>NDC <span class="Bold">49281-880-03</span></p>
<p><span class="Bold">BCG Live<br>(Intravesical)</span></p>
<p><span class="Bold Italics">THERACYS</span><span class="Sup">®</span></p>
<p>For treatment and prophylaxis of superficial<br>transitional cell carcinoma of the urinary bladder</p>
<p><span class="Bold">BCG</span></p>
<p>1 Dose</p>
<p><span class="Italics">Rx only</span></p>
<p><span class="Bold">SANOFI</span> PASTEUR</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 81 mg Vial Carton (No Diluent)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e456333-5a25-4484-84bf-53ece67c000a&amp;name=theracys-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>THERACYS 		
					</strong><br><span class="contentTableReg">bacillus calmette-guerin substrain connaught live antigen injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">VACCINE LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49281-880</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVESICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BACILLUS CALMETTE-GUERIN SUBSTRAIN CONNAUGHT LIVE ANTIGEN</strong> (BACILLUS CALMETTE-GUERIN SUBSTRAIN CONNAUGHT LIVE ANTIGEN) </td>
<td class="formItem">BACILLUS CALMETTE-GUERIN SUBSTRAIN CONNAUGHT LIVE ANTIGEN</td>
<td class="formItem">81 mg  in 3 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MONOSODIUM GLUTAMATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-880-03</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-880-58</td>
<td class="formItem">3 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103943</td>
<td class="formItem">07/22/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sanofi Pasteur Inc.
							(086723285)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Pasteur Limited</td>
<td class="formItem"></td>
<td class="formItem">208206623</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6fd44443-0288-4e69-a3ef-6af6a1d10104</div>
<div>Set id: 8e456333-5a25-4484-84bf-53ece67c000a</div>
<div>Version: 9</div>
<div>Effective Time: 20130930</div>
</div>
</div> <div class="DistributorName">Sanofi Pasteur Inc.</div></p>
</body></html>
